Pharmacokinetics of the Antiarrhythmic Disopyramide in Healthy Humans

Overview

Journal J Pharmacokinet Biopharm

Specialty Pharmacology

Date 1976 Jun 1

PMID 978389

Citations 43

Authors

P H Hinderling

E R GARRETT

Affiliations

Soon will be listed here.

Citing Articles

Therapeutic drug monitoring: antiarrhythmic drugs.

Campbell T, Williams K Br J Clin Pharmacol. 1998; 46(4):307-19.

PMID: 9803978 PMC: 1874159. DOI: 10.1046/j.1365-2125.1998.t01-1-00768.x.

A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes.

Jones H, KELLY H, Hutchison M, YATES R, Ross F, Lomax C Eur J Drug Metab Pharmacokinet. 1997; 22(3):193-9.

PMID: 9358198 DOI: 10.1007/BF03189806.

Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.

Johnston A, Henry J, Warrington S, HAMER N Br J Clin Pharmacol. 1980; 10(3):245-8.

PMID: 7437241 PMC: 1430074. DOI: 10.1111/j.1365-2125.1980.tb01751.x.

Plasma binding of disopyramide.

David B, Madsen B, Ilett K Br J Clin Pharmacol. 1980; 9(6):614-8.

PMID: 7387819 PMC: 1430006. DOI: 10.1111/j.1365-2125.1980.tb01090.x.

Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.

Forssell G, Graffner C, Nordlander R, Nyquist O Eur J Clin Pharmacol. 1980; 17(3):209-13.

PMID: 7363933 DOI: 10.1007/BF00561902.

References

Granier J . [A new antiarrhythmic agent: disopyramide]. Presse Med (1893). 1968; 76(32):1605-6. View

Du Bois D, Du Bois E . A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989; 5(5):303-11; discussion 312-3. View

Jusko W, Lewis G, DITTERT L . Integral coefficients of multi-compartment pharmacokinetic models. Application to chemotherapy. Chemotherapy. 1972; 17(2):109-20. DOI: 10.1159/000220844. View

Hutsell T, Stachelski S . Determination of disopyramide and its mono-N-dealkylated metabolite in blood serum and urine. J Chromatogr. 1975; 106(1):151-8. DOI: 10.1016/s0021-9673(01)81057-8. View

Gibaldi M, Feldman S . Pharmacokinetic basis for the influence of route of administration on the area under the plasma concentration-time curve. J Pharm Sci. 1969; 58(12):1477-80. DOI: 10.1002/jps.2600581211. View

Gibaldi M, Feldman S . Route of administration and drug metabolism. Eur J Pharmacol. 1972; 19(3):323-9. DOI: 10.1016/0014-2999(72)90098-2. View

Rowland M . Influence of route of administration on drug availability. J Pharm Sci. 1972; 61(1):70-4. DOI: 10.1002/jps.2600610111. View

Vismara L, Mason D, Amsterdam E . Disopyramide phosphate: clinical efficacy of a new oral antiarrhythmic drug. Clin Pharmacol Ther. 1974; 16(2):330-5. DOI: 10.1002/cpt1974162330. View

Hartel G, LOUHIJA A, KONTTINEN A . Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharmacol Ther. 1974; 15(6):551-5. DOI: 10.1002/cpt1974156551. View

10.

Sekiya A, VAUGHANWILLIAMS E . A COMPARISON OF THE ANTIFIBRILLATORY ACTIONS AND EFFECTS ON INTRACELLULAR CARDIAC POTENTIALS OF PRONETHALOL, DISOPYRAMIDE AND QUINIDINE. Br J Pharmacol Chemother. 1963; 21:473-81. PMC: 1703883. DOI: 10.1111/j.1476-5381.1963.tb02015.x. View

11.

Gibaldi M, BOYES R, Feldman S . Influence of first-pass effect on availability of drugs on oral administration. J Pharm Sci. 1971; 60(9):1338-40. DOI: 10.1002/jps.2600600909. View

12.

Yeh B, Sung P, Scherlag B . Effects of disopyramide on electrophysiological and mechanical properties of the heart. J Pharm Sci. 1973; 62(12):1924-9. DOI: 10.1002/jps.2600621203. View

13.

NOTARI R, DeYoung J, REUNING R . Effect of parallel first-order loss from site of administration on calculated values for absorption rate constants. J Pharm Sci. 1972; 61(1):135-8. DOI: 10.1002/jps.2600610133. View

14.

TOBIAS G, MCLAUGHLIN Jr R, HOPPER Jr J . Endogenous creatinine clearance. A valuable clinical test of glomerular filtration and a prognostic guide in chronic renal disease. N Engl J Med. 1962; 266:317-23. DOI: 10.1056/NEJM196202152660701. View

15.

RANNEY R, Dean R, Karim A, Radzialowski F . Disopyramide phosphate: pharmacokinetic and pharmacologic relationships of a new antiarrhythmic agent. Arch Int Pharmacodyn Ther. 1971; 191(1):162-88. View

16.

GIBSON J, Evans W . CLINICAL STUDIES OF THE BLOOD VOLUME. I. CLINICAL APPLICATION OF A METHOD EMPLOYING THE AZO DYE "EVANS BLUE" AND THE SPECTROPHOTOMETER. J Clin Invest. 1937; 16(3):301-16. PMC: 424872. DOI: 10.1172/JCI100859. View

17.

COFFEY J . Effects of protein bindings of drugs on areas under plasma concentration--time curves. J Pharm Sci. 1972; 61(1):138-9. DOI: 10.1002/jps.2600610134. View

18.

Turiel S, Smith W . A seminar on Norpace (disopyramide phosphate) a new antiarrhythmic agent. Introductory remarks. Angiology. 1975; 26(1 Pt 2):65-6. View

19.

Karim A, RANNEY R, KRAYCHY S . Species differences in the biotransformation of a new antiarrhythmic agent: disopyramide phosphate. J Pharm Sci. 1972; 61(6):888-93. DOI: 10.1002/jps.2600610612. View

20.

Katz M, Meyer C, EL-ETR A, SLODKI S . Clinical evaluation of a new anti-arrhythmic agent, SC-7031. Curr Ther Res Clin Exp. 1963; 5:343-50. View